Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights Transcript
Source: SeekingAlpha
2026-05-07 09:11:14 ET
Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights May 5, 2026 2:30 PM EDT...
Read the full article on Seeking Alpha
For further details see:
Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights Transcript
Biomea Fusion Inc.
NASDAQ: BMEA
BMEA Trading
-10.37% G/L:
$1.34 Last:
2,396,656 Volume:
$1.49 Open:
BMEA Latest News
June 05, 2026 07:32:00 pm
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association ("ADA") 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
June 03, 2026 08:00:00 am
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
May 11, 2026 04:54:51 pm
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
$94,742,876
57,680,029
0.1%
21
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
